Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
CONCLUSION: Our results showed that the combination of VEN + HMA appeared to be a highly effective and well-tolerated salvage therapy option for young patients with R/R AML, enabling more young patients to proceed to potentially curative allo-HSCT. However, additional, well-designed studies with larger numbers of patients are required to confirm the advantages of VEN + HMA in this population.PMID:37796109 | DOI:10.1080/16078454.2023.2265206
Source: Hematology - Category: Hematology Authors: Xuezhu Xu Rui Liu Aili He Fangxia Wang Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Hematology | Leukemia | Lymphoma | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants